Treatment of locally advanced renal cell carcinoma (cT3–T4, cN0–1, cM0) in patients fit for surgery
This protocol applies to patients with renal cell carcinoma staged cT3 or cT4, cN0–1, cM0 — locally advanced, non-metastatic disease — who are fit for surgery and have resectable tumour.
Clinical scenario
Locally advanced RCC (cT3–T4, cN0–1, cM0) with no confirmed distant metastases, in a patient who is fit for and planned for surgical resection of resectable disease.
Treatment approach
Following nephrectomy, an adjuvant immunotherapy approach may be indicated for eligible patients with clear-cell RCC carrying a defined recurrence risk — with eligibility determined in part by restaging findings and timing after surgery.
Full eligibility criteria, sequencing, and protocol details are in the structured regimen →
References
- cT3-T4 cN0-1 cM0 RCC
- Patients fit for surgery with resectable RCC
- Offer adjuvant pembrolizumab to ccRCC patients, preferably within 12-16 weeks post-nephrectomy, following restaging, with a recurrence risk as defined in the Keynote-564 trial:
- Keynote-564 evaluated pembrolizumab (17 cycles of three-weekly therapy) versus placebo as adjuvant therapy
View source ↗